id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
fbem-7835	Yang, Lan; Ma, Aixia	Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation	2023	7	.pdf	application/pdf	4225	183	51	The quality-adjusted life years (QALYs) and treatment costs of Polatuzumab Vedotin combined with BR regimen and BR regimen alone were compared, and the incremental cost- utility ratio (ICUR) index was calculated. Other parameters, such as follow-up cost, disease management cost, incidence of adverse events and treatment cost, had little effect on ICUR.	cache/fbem-7835.pdf	txt/fbem-7835.txt